Effect of opicapone and entacapone on early morning-OFF pattern in Parkinson’s disease patients with motor fluctuations
Objective: To evaluate the effect of opicapone (OPC) 50 mg versus entacapone (ENT) on early morning-OFF (EMO) pattern. Background: OPC, a once-daily catechol-O-methyltransferase inhibitor, was…Opicapone in Parkinson’s disease – a centre’s real-life experience
Objective: To evaluate the therapeutic benefits, safety and tolerability of opicapone in a centre’s clinical practice. Background: Opicapone is a recent treatment for motor fluctuations…Efficacy and Safety of Opicapone in Parkinson’s Disease Patients According to Duration of Motor Fluctuations: Post-Hoc Analysis of BIPARK-I and II
Objective: This exploratory post-hoc analysis evaluated the efficacy and safety of opicapone (OPC) in levodopa-treated Parkinson’s disease (PD) patients with duration of motor fluctuations of…Opicapone’s added benefit as a first-line adjunctive therapy to levodopa and when used promptly in the motor fluctuations spectrum of Parkinson’s disease: a post-hoc analysis of BIPARK-I and II
Objective: To evaluate opicapone (OPC) in Parkinson’s disease (PD) patients with motor fluctuations according to disease- and therapy-related characteristics. Background: OPC, a once-daily catechol-O-methyltransferase inhibitor,…Efficacy of opicapone compared to entacapone in catechol-O-methyltransferase inhibitor-naïve Parkinson’s disease patients recently diagnosed with motor fluctuations: A post-hoc conservative analysis
Objective: To assess the efficacy of opicapone 50 mg (OPC 50 mg), compared with entacapone (ENT), in catechol-O-methyltransferase inhibitor (COMTi)-naïve Parkinson’s disease (PD) patients recently…Opicapone as First-Line Adjunctive Levodopa Treatment in Parkinson’s Disease Patients with Motor Fluctuations: Findings from BIPARK-I and II Combined Post-Hoc Analysis
Objective: This exploratory post-hoc analysis evaluated the efficacy and safety of opicapone (OPC) as first-line adjunctive therapy in levodopa/DOPA decarboxylase inhibitors-treated Parkinson’s disease (PD) patients…Efficacy and tolerability of opicapone in Parkinson´s disease in usual clinical practice
Objective: To evaluate the efficacy and tolerability of opicapone in usual clinical practice in patients with Parkinson's disease (PD). Background: Opicapone is a recently approved…Characterization of the pattern of daily motor fluctuations in Parkinson’s disease patients based on home diaries
Objective: Home diary-based representation of patients’ daily motor status. Background: Parkinson’s disease (PD) patients are often in their best clinical state when attending medical appointments.…Effect of opicapone and entacapone on daily pattern of motor fluctuations in Parkinson’s disease patients
Objective: To evaluate the effect of opicapone (OPC) 50 mg versus entacapone (ENT) on daily pattern of motor fluctuations. Background: OPC, a once-daily catechol-O-methyltransferase inhibitor,…Efficacy and safety/tolerability of opicapone in catechol-O-methyltransferase inhibitor-naïve Parkinson’s disease patients recently diagnosed with motor fluctuations
Objective: To evaluate the potential added benefit of opicapone (OPC), compared with placebo (PLC) and entacapone (ENT), in catechol-O-methyltransferase inhibitor (COMTi)-naïve Parkinson’s disease (PD) patients…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 12
- Next Page »